NCT00457119 - Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

RAD001

5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm

Trial Locations (8)

Novartis Investigative Site, Heidelberg

Novartis Investigative Site, Adelaide

Novartis Investigative Site, Essen

Novartis Investigative Site, Heidelberg

LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center, New Orleans

Georgetown University/Lombardi Cancer Center StudyCoordinator:CRAD001C2114, Washington D.C.

U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office, Dallas

MD Anderson Cancer Center/University of Texas Thoractic Head/Neck Med. Onc., Houston